US$ 28.63
what are the names of the glp 1 medications trade GLP-1 glp 1 receptor agonists brand
Description
CrossRef A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity Kazuhiro Kashiwagi, Michiyo Takayama, Kayoko Fukuhara, Ryoko Shimizu-Hirota, Po-Sung Chu, Nobuhiro Nakamoto, Nagamu Inoue, Yasushi Iwao, Takanori Kanai Clinical Nutrition ESPEN.2020

Trends Biochem Sci 33:314319

Additionally, in a 72-week Phase 2 trial in patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, F3

But these were different trials, different populations, and different primary endpoints
